Literature DB >> 11837244

Combination of alpha-stat strategy and hemodilution exacerbates neurologic injury in a survival piglet model with deep hypothermic circulatory arrest.

Takahiko Sakamoto1, David Zurakowski, Lennart F Duebener, Shinichi Hatsuoka, Hart G W Lidov, Gregory L Holmes, Ulrich A Stock, Peter C Laussen, Richard A Jonas.   

Abstract

BACKGROUND: The optimal pH strategy and hematocrit during cardiopulmonary bypass with deep hypothermic circulatory arrest (DHCA) remain controversial. We studied the interaction of pH strategy and hematocrit and their combined impact on cerebral oxygenation and neurological outcome in a survival piglet model including monitoring by near-infrared spectroscopy (NIRS).
METHODS: Thirty-six piglets (9.2+/-1.1 kg) underwent DHCA under varying conditions with continuous monitoring by NIRS (pH-stat or alpha-stat strategy, hematocrit 20% or 30%, DHCA time 60, 80, or 100 minutes). Neurological recovery was evaluated daily. The brain was fixed in situ on postoperative day 4 and a histological score (HS) for neurological injury was assessed.
RESULTS: Oxygenated hemoglobin (HbO2) and total hemoglobin signals detected by NIRS were significantly lower with alpha-stat strategy during cooling (p < 0.001), suggesting insufficient cerebral blood supply and oxygenation. HbO2 declined to a plateau (nadir) during DHCA. Time to nadir was significantly shorter in lower hematocrit groups (p < 0.01). Significantly delayed neurologic recovery was seen with alpha-stat strategy compared with pH-stat (p < 0.05). The alpha-stat group had a worse histological score compared with those assigned to pH-stat (p < 0.001). Neurologic impairment was estimated to be over 10 times more likely for animals randomized to alpha-stat compared with pH-stat strategy (odds ratio = 10.7, 95% confidence interval = 3.8 to 25.2).
CONCLUSIONS: Combination of alpha-stat strategy and lower hematocrit exacerbates neurological injury after DHCA. The mechanism of injury is inadequate cerebral oxygenation during cooling and a longer plateau period of minimal O2 extraction during DHCA.

Entities:  

Mesh:

Year:  2002        PMID: 11837244     DOI: 10.1016/s0003-4975(01)03274-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Current status of brain protection during surgery for congenital cardiac defect.

Authors:  Takahiko Sakamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-11-30

2.  Cerebral protection in hemi-aortic arch surgery.

Authors:  Mohamad Bashir; Matthew Shaw; Michael Desmond; Manoj Kuduvalli; Mark Field; Aung Oo
Journal:  Ann Cardiothorac Surg       Date:  2013-03

Review 3.  Varying Evidence on Deep Hypothermic Circulatory Arrest in Thoracic Aortic Aneurysm Surgery.

Authors:  Prity Gupta; Amer Harky; Saleem Jahangeer; Benjamin Adams; Mohamad Bashir
Journal:  Tex Heart Inst J       Date:  2018-04-07

4.  Effect of deep hypothermic circulatory arrest followed by low-flow cardiopulmonary bypass on brain metabolism in newborn piglets: comparison of pH-stat and α-stat management.

Authors:  Afsaneh Pirzadeh; Gregory Schears; Peter Pastuszko; Huiping Liu; Joanna Kubin; Erin Reade; Alberto Mendoza-Paredes; William Greeley; Vinay Nadkarni; David F Wilson; Anna Pastuszko
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

5.  Cerebral oximetry monitoring during preoperative phlebotomy to limit allogeneic blood use in patients undergoing cardiac surgery.

Authors:  Elisabeth Dewhirst; Peter Winch; Aymen Naguib; Mark Galantowicz; Joseph D Tobias
Journal:  Pediatr Cardiol       Date:  2012-06-01       Impact factor: 1.655

6.  Evaluation of neuronal apoptosis precursors in an experimental model of acute normovolemic hemodilution.

Authors:  Fabrício O Frazilio; Denise Aya Otsuki; Jessica Noel-Morgan; Jessica Ruivo Maximino; Gabriela Pintar Oliveira; Gerson Chadi; Jose Otavio Costa Auler; Denise Tabacchi Fantoni
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.